Vyleesi: A New Era for Female Sexual Health
Vyleesi (Bremelanotide) is an FDA-approved prescription medication for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by a persistent lack of interest in sex that causes personal distress. Vyleesi offers a novel approach to treating this condition by working on the brain's pathways that control sexual desire.
Mechanism of Action: Targeting the Brain's Desire Centers
Unlike other treatments for sexual dysfunction that focus on hormonal or vascular mechanisms, Vyleesi is a melanocortin receptor agonist. It is thought to work by activating specific melanocortin receptors in the central nervous system. This activation is believed to modulate the brain pathways that play a role in sexual response, leading to an increase in sexual desire. The exact mechanism of action is not fully understood, but it represents a significant shift in the understanding and treatment of female sexual dysfunction.
Clinical Evidence: The RECONNECT Studies
The FDA approval of Vyleesi was based on the results of two large, randomized, placebo-controlled phase 3 clinical trials known as the RECONNECT studies. These studies evaluated the efficacy and safety of Vyleesi in over 1,200 premenopausal women with HSDD. The key findings from these studies were:
- Increased Sexual Desire: Women treated with Vyleesi experienced a statistically significant increase in their sexual desire, as measured by the Female Sexual Function Index (FSFI).
- Decreased Distress: Vyleesi also led to a significant decrease in the distress that women felt about their low sexual desire, as measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO).
| Endpoint | Vyleesi | Placebo |
|---|---|---|
| Change in FSFI Desire Domain Score | Statistically significant increase | Less significant increase |
| Change in FSDS-DAO Item 13 Score | Statistically significant decrease | Less significant decrease |
These results demonstrate that Vyleesi is an effective treatment for improving sexual desire and reducing related distress in premenopausal women with HSDD [1].
Dosing and Administration
Vyleesi is self-administered as a subcutaneous injection in the abdomen or thigh, as needed, at least 45 minutes before anticipated sexual activity. The recommended dose is 1.75 mg. It is important to follow the dosing instructions provided by a healthcare professional. Vyleesi should not be used more than once in 24 hours or more than eight times per month.
Safety Profile and Common Side Effects
The most common side effects reported in the clinical trials of Vyleesi include:
- Nausea: This was the most frequent side effect, and it was generally mild to moderate.
- Flushing: A temporary reddening of the skin.
- Injection Site Reactions: Pain, redness, or bruising at the injection site.
- Headache: A common side effect.
Vyleesi can also cause a temporary increase in blood pressure and a decrease in heart rate. Therefore, it is not recommended for women with uncontrolled high blood pressure or known cardiovascular disease.
Key Takeaways
- Vyleesi (Bremelanotide) is an FDA-approved treatment for HSDD in premenopausal women.
- It is a melanocortin receptor agonist that works on the central nervous system to increase sexual desire.
- Clinical trials have demonstrated its efficacy in improving sexual desire and reducing related distress.
- The most common side effects are nausea, flushing, and injection site reactions.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any peptide therapy or making changes to your health regimen.
References
[1] Kingsberg, S. A., Clayton, A. H., Portman, D., et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized, Multicenter, Placebo-Controlled Trials. Obstetrics and gynecology, 134(5), 899–908. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819021/ [2] Vyleesi (bremelanotide injection), for subcutaneous use. (2019). FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf [3] Simon, J. A., Kingsberg, S. A., Goldstein, I., et al. (2019). Bremelanotide for the treatment of premenopausal women with hypoactive sexual desire disorder: A pooled analysis of the RECONNECT studies. The journal of sexual medicine, 16(11), 1779–1789.